Skip to main content

Advertisement

SpringerLink
Log in

A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction

  • PHASE II STUDIES
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Purpose To evaluate the antitumor activity of SP1049C, a novel P-glycoprotein targeting micellar formulation of doxorubicin, consisting of doxorubicin and two non-ionic block copolymers (pluronics), in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction (GEJ). Patients and Methods Patients with metastatic or locally advanced unresectable adenocarcinoma of the esophagus or GEJ who had not previously received systemic chemotherapy and had measurable disease were treated with SP1049C 75 mg/m2 (doxorubicin equivalents) as a brief intravenous infusion every 3 weeks until disease progression or unacceptable toxicity. The primary endpoint was the objective response rate in patients who had received a least one course of SP1049C and had undergone tumor assessment, whereas, secondary endpoints included the objective response rate, progression-free survival (PFS), overall survival, and safety in the intent-to-treat (ITT) population. A review of scans was also conducted post-hoc by a blinded panel of radiologists. Results Twenty-one patients, of which 19 were evaluable for response, were treated with at least one dose of SP1049C. Nine patients had a partial response (PR) and eight patients had either a minor response or stable disease as their best response. The objective response rate was 47% (95% CI: 24.4–71) in the evaluable patient population, whereas the objective response rate was 43% (95% CI: 21.8–65.9) in the ITT population. The post-hoc radiological review confirmed that all nine responders had a PR; seven of the nine had a PR that was confirmed by a subsequent scan, whilst two patients had unconfirmed PRs. The median overall survival and PFS were 10.0 months (95%CI: 4.8–11.2) and 6.6 months (95% CI: 4.5–7.6), respectively. Neutropenia was the principal toxicity of SP1049C. Four patients developed an absolute percentage decrement of at least 15% in their left ventricular ejection fraction, none of which decreased to below 45% nor were symptomatic. Conclusion SP1049C has a notable single-agent activity in patients with adenocarcinoma of the esophagus and GEJ, as well as an acceptable safety profile. These results, in addition to the results of preclinical studies demonstrating superior antitumor activity of SP1049C compared with doxorubicin in a standard formulation, indicate that further evaluations of SP1049C alone or combined with other relevant therapeutics in this disease setting are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Blot WJ, Devesa SS, Kneller RW, Fraumeni JF Jr (1991) Rising incidence of adenocarcinoma of the esophagus and gastric cardia. JAMA 265:1287–1289

    Article  PubMed  CAS  Google Scholar 

  2. Botterweck AA, Schouten LJ, Volovics A, Dorant E, van Den Brandt PA (2000) Trends in incidence of adenocarcinoma of the oesophagus and gastric cardia in ten European countries. Int J Epidemiol 29:645–654

    Article  PubMed  CAS  Google Scholar 

  3. Pohl H, Welch HG (2005) The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 97:142–146

    Article  PubMed  Google Scholar 

  4. Hampel H, Abraham NS, El-Serag HB (2005) Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications. Ann Intern Med 143:199–211

    PubMed  Google Scholar 

  5. Kubo A, Corley DA (2006) Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15:872–878

    Article  PubMed  Google Scholar 

  6. Lagergren J, Bergström R, Lindgren A, Nyrén O (1999) Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 340:825–831

    Article  PubMed  CAS  Google Scholar 

  7. Yeoh KG (2007) How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol 22:970–972

    Article  PubMed  Google Scholar 

  8. Eloubeidi MA, Mason AC, Desmond RA, El-Serag HB (2003) Temporal trends (1973–1997) in survival of patients with esophageal adenocarcinoma in the United States: a glimmer of hope? Am J Gastroenterol 98:1627–1633

    PubMed  Google Scholar 

  9. Pisters WTP, Kelsen DP, Tepper JE (2008) Cancer of the stomach. In: DeVita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 1043–1079

    Google Scholar 

  10. Posner MC, Minsky BD, Ilson DH (2008) Cancer of the esophagus. In: DeVita VT et al (eds) Cancer principles and practice of oncology, 8th edn. Lippincott Williams and Wilkins, Philadelphia, pp 993–1042

    Google Scholar 

  11. Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909

    Article  PubMed  CAS  Google Scholar 

  12. Ferlay J, Autier P, Boniol M et al (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581–592

    Article  PubMed  CAS  Google Scholar 

  13. Van Cutsem E, Moiseyenko VM, Tjulandin S et al (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24:4991–4997

    Article  PubMed  Google Scholar 

  14. Glimelius B, Ekstrom K, Hoffman K et al (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163–168

    Article  PubMed  CAS  Google Scholar 

  15. Homs MY, Gaast A, Siersema PD, et al (2006) Chemotherapy for metastatic carcinoma of the esophagus and gastroesophageal junction. Cochrane Database Syst Rev CD004063

  16. Ilson DH (2002) Epirubicin, cisplatin, and fluorouracil in gastric and oesophageal cancer: a step ahead? J Clin Oncol 20:1962–1964

    PubMed  Google Scholar 

  17. Ilson DH (2003) Esophageal cancer: new developments in systemic therapy. Cancer Treat Rev 29:525–532

    Article  PubMed  Google Scholar 

  18. Ilson DH (2006) Cancer of the gastroesophageal junction: current therapy options. Curr Treat Options in Oncol 7:410–423

    Article  Google Scholar 

  19. Ilson DH (2007) Docetaxel, cisplatin, and fluorouracil in gastric cancer: does the punishment fit the crime? J Clin Oncol 25:3188–3190

    Article  PubMed  CAS  Google Scholar 

  20. Swisher SG, Pisters PWT, Komaki R, Lahoti S, Ajani JA (2000) Gastroesophageal junction adenocarcinoma. Curr Treat Options in Oncol 1:387–398

    Article  CAS  Google Scholar 

  21. Shah MA, Ramanathan RK, Ilson DH et al (2006) Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24:5201–5206

    Article  PubMed  CAS  Google Scholar 

  22. Assersohn L, Brown G, Cunningham D et al (2004) Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced esophageal and gastric carcinoma. Ann Oncol 15:64–69

    Article  PubMed  CAS  Google Scholar 

  23. Barone C, Basso M, Schinzari G et al (2007) Docetaxel and oxaliplatin combination in second-line treatment of patients with advanced gastric cancer. Gastric Cancer 10:104–111

    Article  PubMed  CAS  Google Scholar 

  24. Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46

    Article  PubMed  CAS  Google Scholar 

  25. Van Cutsem E, Van de Velde C, Roth A et al (2008) Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC)-gastrointestinal cancer group. Eur J Cancer 44:182–194

    Article  PubMed  Google Scholar 

  26. Higgins CF (2007) Multiple molecular mechanisms for multidrug resistance transporters. Nature 446:749–757

    Article  PubMed  CAS  Google Scholar 

  27. Callaghan R, Ford RC, Kerr ID (2006) The translocation mechanism of P-glycoprotein. FEBS Lett 580:1056–1063

    Article  PubMed  CAS  Google Scholar 

  28. Collet JH (2003) Poloxamers. In: Rowe RC, Sheskey P, Weller PJ (eds) Handbook of pharmaceutical excipients. American Pharmaceutical Association, Washington, DC, pp 447–450

    Google Scholar 

  29. Alakhov V, Klinski E, Li S et al (1999) Block copolymer-based formulation of doxorubicin. From cell screen to clinical trials. Colloids Surf B: Biointerfaces 16:113–134

    Article  CAS  Google Scholar 

  30. Batrakova EV, Li S, Elmquist WF et al (2001) Mechanism of sensitization of MDR cancer cells by Pluronic block copolymers: selective energy depletion. Br J Cancer 85:1987–1997

    Article  PubMed  CAS  Google Scholar 

  31. Venne A, Li S, Mandeville R et al (1996) Hypersensitizing effect of pluronic L61 on cytotoxic activity, transport, and subcellular distribution of doxorubicin in multiple drug-resistant cells. Cancer Res 56:3626–3629

    PubMed  CAS  Google Scholar 

  32. Batrakova EV, Kelly DL, Li S et al (2006) Alteration of genomic responses to doxorubicin and prevention of MDR in breast cancer cells by a polymer excipient: pluronic P85. Mol Pharm 3:113–123

    Article  PubMed  CAS  Google Scholar 

  33. Batrakova EV, Li S, Li Y, Alakhov VY, Kabanov AV (2004) Effect of pluronic P85 on ATPase activity of drug efflux transporters. Pharm Res 21:2226–2233

    Article  PubMed  CAS  Google Scholar 

  34. Danson S, Ferry D, Alakhov V et al (2004) Phase I dose escalation and pharmacokinetic study of pluronic polymer-bound doxorubicin (SP1049C) in patients with advanced cancer. Br J Cancer 90:2085–2091

    PubMed  CAS  Google Scholar 

  35. Gehan EA (1961) The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis 13:346–353

    Article  PubMed  CAS  Google Scholar 

  36. Waters JS, Norman A, Cunningham D et al (1999) Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial. Br J Cancer 80:269–272

    Article  PubMed  CAS  Google Scholar 

  37. Webb A, Cunningham D, Scarffe JH et al (1997) Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261–267

    PubMed  CAS  Google Scholar 

  38. McDevitt CA, Callaghan R (2007) How can we best use structural information on P-glycoprotein to design inhibitors? Pharmacol Ther 113:429–441

    Article  PubMed  CAS  Google Scholar 

  39. Pérez-Tomás R (2006) Multidrug resistance: retrospect and prospects in anti-cancer drug treatment. Curr Med Chem 13:1859–1876

    Article  PubMed  Google Scholar 

  40. Nobili S, Landini I, Giglioni B et al (2006) Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7:861–879

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology, Christie Hospital NHS Trust, Wilmslow Road, Manchester, M20 4BX, UK

    Juan W. Valle, Anne Armstrong, Julie Brewer & Malcolm Ranson

  2. University of Manchester, Oxford Road, Manchester, M13 9PL, UK

    Juan W. Valle & Malcolm Ranson

  3. Supratek Pharma Inc., Dorval, QC, H9S 5T8, Canada

    Chris Newman, Valery Alakhov, Grzegorz Pietrzynski, Sue Campbell & Eric K. Rowinsky

  4. Addenbrookes Hospital, Hills Road, Cambridge, CB2 2QQ, UK

    Pippa Corrie

Authors
  1. Juan W. Valle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anne Armstrong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chris Newman
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Valery Alakhov
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Grzegorz Pietrzynski
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Julie Brewer
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Sue Campbell
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Pippa Corrie
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Eric K. Rowinsky
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Malcolm Ranson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Juan W. Valle.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Valle, J.W., Armstrong, A., Newman, C. et al. A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Invest New Drugs 29, 1029–1037 (2011). https://doi.org/10.1007/s10637-010-9399-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-010-9399-1

Keywords

Search

Navigation